

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use SPIKEVAX safely and effectively. See full prescribing information for SPIKEVAX.

SPIKEVAX (COVID-19 Vaccine)
Suspension for Intramuscular Injection
Initial U.S. Approval: 2021

-----INDICATIONS AND USAGE-----

SPIKEVAX is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older. (1)

-----DOSAGE AND ADMINISTRATION-----

Administered intramuscularly as a series of two doses (0.5 mL each) 1 month apart. (2.3)

-----DOSAGE FORMS AND STRENGTHS-----

Suspension for injection supplied in two presentations:

- 5.5 mL multiple-dose vial (3)
- 7.5 mL multiple-dose vials (3)

-----CONTRAINDICATIONS-----

Severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine. (4)

-----WARNINGS AND PRECAUTIONS-----

- Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine. (5.1)
- Risk of myocarditis and/or pericarditis; consider individual’s clinical history. (5.2)

-----ADVERSE REACTIONS-----

Most common adverse reactions were pain at the injection site, fatigue, headache, myalgia, arthralgia, chills, nausea/vomiting, axillary swelling/tenderness, fever, swelling at the injection site, and erythema at the injection site. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact ModernaTX, Inc. at 1-866-663-3762 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 00/2021

FULL PRESCRIBING INFORMATION: CONTENTS*

- 1 INDICATIONS AND USAGE**
- 2 DOSAGE AND ADMINISTRATION**
 - 2.1 Preparation for Administration
 - 2.2 Administration
 - 2.3 Dosing and Schedule
- 3 DOSAGE FORMS AND STRENGTHS**
- 4 CONTRAINDICATIONS**
- 5 WARNINGS AND PRECAUTIONS**
 - 5.1 Management of Acute Allergic Reactions
 - 5.2 Myocarditis and Pericarditis
 - 5.3 Altered Immunocompetence
 - 5.4 Limitations of Vaccine Effectiveness
- 6 ADVERSE REACTIONS**
 - 6.1 Clinical Trials Experience
 - 6.2 Emergency Use Experience

- 7 DRUG INTERACTIONS**
- 8 USE IN SPECIFIC POPULATIONS**
 - 8.1 Pregnancy
 - 8.2 Lactation
 - 8.4 Pediatric Use
 - 8.5 Geriatric Use
- 11 DESCRIPTION**
- 12 CLINICAL PHARMACOLOGY**
 - 12.1 Mechanism of Action
- 13 NONCLINICAL TOXICOLOGY**
 - 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
- 14 CLINICAL STUDIES**
- 16 HOW SUPPLIED/STORAGE AND HANDLING**
- 17 PATIENT COUNSELING INFORMATION**

*Sections or subsections omitted from the full prescribing information are not listed

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

SPIKEVAX is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older. [2.5.6.5]

2 DOSAGE AND ADMINISTRATION

For intramuscular injection only. [2.5.1.1.2, 2.5.1.4.2]

2.1 Preparation for Administration

- SPIKEVAX multiple-dose vials contain a frozen suspension that does not contain a preservative and must be thawed prior to administration. [BLA 125752 SN002 3.2.P.2.1]
- Remove the required number of vial(s) from storage and thaw each vial before use following the instructions below. [BLA 125752 SN002 3.2.P.2.2]

Vial	Thaw in Refrigerator	Thaw at Room Temperature
5.5 mL Vial	Thaw in refrigerated conditions between 2° to 8°C (36° to 46°F) for 2 hours and 30 minutes. Let each vial stand at room temperature for 15 minutes before administering.	Alternatively, thaw at room temperature between 15° to 25°C (59° to 77°F) for 1 hour.
7.5 mL Vial	Thaw in refrigerated conditions between 2° to 8°C (36° to 46°F) for 3 hours. Let each vial stand at room temperature for 15 minutes before administering.	Alternatively, thaw at room temperature between 15° to 25°C (59° to 77°F) for 1 hour and 30 minutes.

- After thawing, do not refreeze. [BLA 125752 SN002 3.2.P.2.2, 3.2.P.2.6]
- Swirl vial gently after thawing and between each withdrawal. **Do not shake.** [BLA 125752 SN002 3.2.P.2.6] Do not dilute the vaccine. [BLA 125752 SN002 3.2.P.1, 3.2.P.2.6]
- SPIKEVAX is a white to off-white suspension. It may contain white or translucent product-related particulates. [BLA 125752 SN002 3.2.P.2.1, 3.2.P.5.1] Visually inspect SPIKEVAX vials for other particulate matter and/or discoloration prior to administration. If either of these conditions exists, the vaccine should not be administered. [BLA 125752 SN002 3.2.P.2.6]
- Each dose is 0.5 mL. [2.5.1.1.2, 2.5.1.4.2, 2.5.3.1]

- If the amount of vaccine remaining in the vial cannot provide a full dose of 0.5 mL, discard the vial and contents. Do not pool excess vaccine from multiple vials. [BLA 125752 SN002 3.2.P.2.6]
- After the first dose has been withdrawn, the vial should be held between 2° to 25°C (36° to 77°F). [BLA 125752 SN002 3.2.P.2.5, 3.2.P.2.6, 3.2.P.8.1, 3.2.P.8.3] Record the date and time of first use on the SPIKEVAX vial label. Discard vial after 12 hours. Do not refreeze. [BLA 125752 SN002 3.2.P.2.5, 3.2.P.2.6]

2.2 Administration

Visually inspect each dose of SPIKEVAX in the dosing syringe prior to administration. The white to off-white suspension may contain white or translucent product-related particulates. [BLA 125752 SN002 3.2.P.2.1, 3.2.P.5.1] During the visual inspection:

- Verify the final dosing volume of 0.5 mL. [2.5.1.1.2, 2.5.1.4.2, 2.5.3.1]
- Confirm there are no other particulates and that no discoloration is observed. [BLA 125752 SN002 3.2.P.2.6]
- Do not administer if vaccine is discolored or contains other particulate matter. [BLA 125752 SN002 3.2.P.2.6]

Administer SPIKEVAX intramuscularly. [2.5.1.1.2, 2.5.1.4.2]

2.3 Dosing and Schedule

SPIKEVAX is administered intramuscularly as a series of two doses (0.5 mL each) 1 month apart. [2.5.1.1.2, 2.5.1.4.2, 2.5.3.1]

There are no data available on the interchangeability of SPIKEVAX with other COVID-19 vaccines to complete the vaccination series. Individuals who have received one dose of SPIKEVAX should receive a second dose of SPIKEVAX to complete the vaccination series.

3 DOSAGE FORMS AND STRENGTHS

SPIKEVAX is a suspension for intramuscular injection supplied in two presentations: [BLA SN002 125752 3.2.P.1]

- 5.5 mL multiple dose vial
- 7.5 mL multiple dose vial

4 CONTRAINDICATIONS

Do not administer SPIKEVAX to individuals with a known history of severe allergic reaction (e.g., anaphylaxis) to any component of SPIKEVAX [see *Description (11)*].

5 WARNINGS AND PRECAUTIONS

5.1 Management of Acute Allergic Reactions

Appropriate medical treatment to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of SPIKEVAX. [2.5.6.3]

5.2 Myocarditis and Pericarditis

Reports of adverse events following use of SPIKEVAX under Emergency Use Authorization use as Moderna COVID-19 Vaccine suggest increased risks of myocarditis and pericarditis, particularly following the second dose. Typically, onset of symptoms has been within a few days following receipt of SPIKEVAX. Available data from short-term follow up suggest that most cases have been mild with resolution of symptoms, but information is not yet available about potential long-term sequelae. The decision to administer SPIKEVAX to an individual with a history of myocarditis or pericarditis should take into account the individual's clinical circumstances. [2.5.6.3]

5.3 Altered Immunocompetence

Immunocompromised persons, including individuals receiving immunosuppressive therapy, may have a diminished response to SPIKEVAX. [2.5.6.2.1]

5.4 Limitations of Vaccine Effectiveness

SPIKEVAX may not protect all vaccine recipients. [2.5.6.2.1]

6 ADVERSE REACTIONS

The most common adverse reactions in participants 18 years of age and older were pain at the injection site (92.0%), fatigue (70.1%), headache (64.9%), myalgia (61.6%), arthralgia (46.5%), chills (45.5%), nausea/vomiting (23.0%), axillary swelling/tenderness (19.9%), fever (15.5%), swelling at the injection site (14.8%), and erythema at the injection site (10.2%). [Table 14.3.1.1.1.3]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a vaccine cannot be directly compared with rates in the clinical trials of another vaccine and may not reflect the rates observed in practice.

The safety of SPIKEVAX was evaluated in a Phase 3 randomized, placebo-controlled, observer-blind clinical trial conducted in the United States involving 30,346 participants 18 years of age and older who received at least one dose of SPIKEVAX (n=15,180) or placebo (n=15,166) (Study 1). [2.5.1.4.2, Table 14.1.1.1.2.2] The median age of the population was 52 years (range

18-95); 22,826 (75.2%) participants were 18 to 64 years of age and 7,520 (24.8%) participants were 65 years of age and older. Overall, 52.6% of the participants were male, 47.4% were female, 20.5% were Hispanic or Latino, 79.2% were White, 10.2% were African American, 4.6% were Asian, 0.8% were American Indian or Alaska Native, 0.2% were Native Hawaiian or Pacific Islander, 2.0% were other races, and 2.1% were Multiracial. [Table 14.1.3.2.2]
Demographic characteristics were similar between participants who received SPIKEVAX and those who received placebo. [2.5.5.3]

Solicited Adverse Reactions

Local and systemic adverse reactions and use of antipyretic medication were solicited in an electronic diary for 7 days following each injection (i.e., day of vaccination and the next 6 days) among participants receiving SPIKEVAX (n=15,179) and participants receiving placebo (n=15,159). Events that persisted for more than 7 days were followed until resolution. Solicited adverse reactions were reported more frequently among vaccine participants than placebo participants. [2.5.5.4.1, Table 14.3.1.1.1.3]

The reported number and percentage of the solicited local and systemic adverse reactions by age group and dose are presented in Table 1 and Table 2, respectively.

Table 1: Number and Percentage of Participants With Solicited Local and Systemic Adverse Reactions Starting Within 7 Days* After Each Dose in Participants 18-64 Years (Solicited Safety Set, Dose 1 and Dose 2) [Table 14.3.1.1.2.1.1, Table 14.3.1.1.2.1.2, Table 14.1.5.5.1, Table 14.1.5.5.2]

	SPIKEVAX		Placebo ^a	
	Dose 1 (N=11,406) n (%)	Dose 2 (N=11,000) n (%)	Dose 1 (N=11,402) n (%)	Dose 2 (N=10,929) n (%)
Local Adverse Reactions				
Pain	9,908 (86.9)	9,893 (89.9)	2,183 (19.1)	2,048 (18.7)
Pain, Grade 3 ^b	366 (3.2)	506 (4.6)	23 (0.2)	22 (0.2)
Axillary swelling/tenderness	1,322 (11.6)	1,777 (16.2)	567 (5.0)	474 (4.3)
Axillary swelling/tenderness, Grade 3 ^b	37 (0.3)	47 (0.4)	13 (0.1)	12 (0.1)
Swelling (hardness) ≥25 mm	766 (6.7)	1,399 (12.7)	42 (0.4)	46 (0.4)
Swelling (hardness), Grade 3 ^c	62 (0.5)	183 (1.7)	3 (<0.1)	5 (<0.1)
Erythema (redness) ≥25 mm	354 (3.1)	989 (9.0)	54 (0.5)	53 (0.5)
Erythema (redness), Grade 3 ^c	34 (0.3)	210 (1.9)	11 (<0.1)	12 (0.1)

	SPIKEVAX		Placebo ^a	
	Dose 1 (N=11,406) n (%)	Dose 2 (N=11,000) n (%)	Dose 1 (N=11,402) n (%)	Dose 2 (N=10,929) n (%)
Systemic Adverse Reactions				
Fatigue	4,385 (38.5)	7,453 (67.8)	3,281 (28.8)	2,701 (24.7)
Fatigue, Grade 3 ^d	121 (1.1)	1,178 (10.7)	83 (0.7)	88 (0.8)
Fatigue, Grade 4 ^e	1 (<0.1)	0 (0)	0 (0)	0 (0)
Headache	4,028 (35.3)	6,929 (63.0)	3,303 (29.0)	2,775 (25.4)
Headache, Grade 3 ^f	220 (1.9)	559 (5.1)	163 (1.4)	132 (1.2)
Myalgia	2,700 (23.7)	6,789 (61.7)	1,625 (14.3)	1,425 (13.0)
Myalgia, Grade 3 ^d	74 (0.6)	1,116 (10.1)	38 (0.3)	42 (0.4)
Arthralgia	1,892 (16.6)	5,010 (45.6)	1,327 (11.6)	1,180 (10.8)
Arthralgia, Grade 3 ^d	47 (0.4)	650 (5.9)	30 (0.3)	37 (0.3)
Arthralgia, Grade 4 ^e	1 (<0.1)	0 (0)	0 (0)	0 (0)
Chills	1,050 (9.2)	5,357 (48.7)	730 (6.4)	662 (6.1)
Chills, Grade 3 ^g	17 (0.1)	164 (1.5)	8 (<0.1)	15 (0.1)
Nausea/vomiting	1,068 (9.4)	2,355 (21.4)	908 (8.0)	807 (7.4)
Nausea/vomiting, Grade 3 ^h	6 (<0.1)	11 (0.1)	8 (<0.1)	8 (<0.1)
Fever	102 (0.9)	1,909 (17.4)	37 (0.3)	38 (0.3)
Fever, Grade 3 ⁱ	10 (<0.1)	185 (1.7)	1 (<0.1)	2 (<0.1)
Fever, Grade 4 ^j	4 (<0.1)	12 (0.1)	4 (<0.1)	2 (<0.1)
Use of antipyretic or pain medication	2,656 (23.3)	6,307 (57.3)	1,523 (13.4)	1,254 (11.5)

* 7 days included day of vaccination and the subsequent 6 days. Events and use of antipyretic or pain medication were collected in the electronic diary (e-diary).

^a Placebo was a saline solution.

^b Grade 3 pain and axillary swelling/tenderness: Defined as any use of prescription pain reliever; prevents daily activity.

^c Grade 3 swelling and erythema: Defined as >100 mm / >10 cm.

^d Grade 3 fatigue, myalgia, arthralgia: Defined as significant; prevents daily activity.

^e Grade 4 fatigue, arthralgia: Defined as requires emergency room visit or hospitalization.

^f Grade 3 headache: Defined as significant; any use of prescription pain reliever or prevents daily activity.

^g Grade 3 chills: Defined as prevents daily activity and requires medical intervention.

^h Grade 3 nausea/vomiting: Defined as prevents daily activity; requires outpatient intravenous hydration.

ⁱ Grade 3 fever: Defined as $\geq 39.0^{\circ} - \leq 40.0^{\circ}\text{C}$ / $\geq 102.1^{\circ} - \leq 104.0^{\circ}\text{F}$.

^j Grade 4 fever: Defined as $>40.0^{\circ}\text{C}$ / $>104.0^{\circ}\text{F}$.

Table 2: Number and Percentage of Participants With Solicited Local and Systemic Adverse Reactions Starting Within 7 Days* After Each Dose in Participants 65 Years and Older (Solicited Safety Set, Dose 1 and Dose 2) [Table 14.3.1.1.2.1.1, Table 14.3.1.1.2.1.2, Table 14.1.5.5.1, Table 14.1.5.5.2]

	SPIKEVAX		Placebo ^a	
	Dose 1 (N=3,760) n (%)	Dose 2 (N=3,691) n (%)	Dose 1 (N=3,749) n (%)	Dose 2 (N=3,649) n (%)
Local Adverse Reactions				
Pain	2,780 (73.9)	3,071 (83.2)	482 (12.9)	438 (12.0)
Pain, Grade 3 ^b	50 (1.3)	100 (2.7)	32 (0.9)	19 (0.5)
Axillary swelling/tenderness	231 (6.1)	315 (8.5)	155 (4.1)	97 (2.7)
Axillary swelling/tenderness, Grade 3 ^b	12 (0.3)	21 (0.6)	14 (0.4)	8 (0.2)
Swelling (hardness) ≥ 25 mm	169 (4.5)	408 (11.1)	23 (0.6)	14 (0.4)
Swelling (hardness), Grade 3 ^c	20 (0.5)	72 (2.0)	3 (<0.1)	7 (0.2)
Erythema (redness) ≥ 25 mm	91 (2.4)	285 (7.7)	23 (0.6)	15 (0.4)
Erythema (redness), Grade 3 ^c	8 (0.2)	77 (2.1)	2 (<0.1)	3 (<0.1)
Systemic Adverse Reactions				
Fatigue	1,251 (33.3)	2,154 (58.4)	852 (22.7)	717 (19.6)
Fatigue, Grade 3 ^d	30 (0.8)	255 (6.9)	22 (0.6)	20 (0.5)
Headache	922 (24.5)	1,708 (46.3)	723 (19.3)	652 (17.9)
Headache, Grade 3 ^c	53 (1.4)	107 (2.9)	34 (0.9)	33 (0.9)
Myalgia	742 (19.7)	1,740 (47.2)	444 (11.9)	399 (10.9)
Myalgia, Grade 3 ^d	17 (0.5)	205 (5.6)	9 (0.2)	10 (0.3)
Arthralgia	618 (16.4)	1,293 (35.1)	457 (12.2)	399 (10.9)
Arthralgia, Grade 3 ^d	13 (0.3)	125 (3.4)	8 (0.2)	7 (0.2)
Chills	201 (5.3)	1,143 (31.0)	148 (4.0)	151 (4.1)

	SPIKEVAX		Placebo ^a	
	Dose 1 (N=3,760) n (%)	Dose 2 (N=3,691) n (%)	Dose 1 (N=3,749) n (%)	Dose 2 (N=3,649) n (%)
Chills, Grade 3 ^f	7 (0.2)	27 (0.7)	6 (0.2)	2 (<0.1)
Nausea/vomiting	194 (5.2)	439 (11.9)	167 (4.5)	134 (3.7)
Nausea/vomiting, Grade 3 ^g	5 (0.1)	10 (0.3)	4 (0.1)	3 (<0.1)
Nausea/vomiting, Grade 4 ^h	0 (0)	1 (<0.1)	0 (0)	0 (0)
Fever	10 (0.3)	367 (9.9)	7 (0.2)	5 (0.1)
Fever, Grade 3 ⁱ	1 (<0.1)	18 (0.5)	1 (<0.1)	0 (0)
Fever, Grade 4 ^j	0 (0)	1 (<0.1)	2 (<0.1)	1 (<0.1)
Use of antipyretic or pain medication	673 (17.9)	1,548 (41.9)	477 (12.7)	331 (9.1)

* 7 days included day of vaccination and the subsequent 6 days. Events and use of antipyretic or pain medication were collected in the electronic diary (e-diary).

^a Placebo was a saline solution.

^b Grade 3 pain and axillary swelling/tenderness: Defined as any use of prescription pain reliever; prevents daily activity.

^c Grade 3 swelling and erythema: Defined as >100 mm / >10 cm.

^d Grade 3 fatigue, myalgia, arthralgia: Defined as significant; prevents daily activity.

^e Grade 3 headache: Defined as significant; any use of prescription pain reliever or prevents daily activity.

^f Grade 3 chills: Defined as prevents daily activity and requires medical intervention.

^g Grade 3 nausea/vomiting: Defined as prevents daily activity; requires outpatient intravenous hydration.

^h Grade 4 nausea/vomiting: Defined as requires emergency room visit or hospitalization for hypotensive shock.

ⁱ Grade 3 fever: Defined as $\geq 39.0^{\circ} - \leq 40.0^{\circ}\text{C}$ / $\geq 102.1^{\circ} - \leq 104.0^{\circ}\text{F}$.

^j Grade 4 fever: Defined as $>40.0^{\circ}\text{C}$ / $>104.0^{\circ}\text{F}$.

Solicited local and systemic adverse reactions reported following administration of SPIKEVAX had a median duration of 1 to 3 days. [2.5.5.4.1]

Grade 3 solicited local adverse reactions were more frequently reported after Dose 2 than after Dose 1. Solicited systemic adverse reactions were more frequently reported by vaccine recipients after Dose 2 than after Dose 1. [2.5.5.4.1]

In Study 1, 2.3% of participants (n=684) were positive for SARS-CoV-2 at baseline (immunologic or virologic evidence of prior COVID-19 infection [defined as positive RT-PCR test and/or positive Elecsys immunoassay result at Day 1]). Among those 684 participants (vaccine=347, placebo=337), rates of solicited ARs were comparable to the 29,491 participants who were baseline negative (negative RT-PCR test and negative Elecsys immunoassay result at Day 1). [Table 14.1.3.2.2, 2.5.5.7.1.1]

The median duration of follow up after the second injection was 6 months. [Table 14.1.6.2.1]

Unsolicited Adverse Events

Participants were monitored for unsolicited adverse events for up to 28 days following each dose and follow up is ongoing. Serious adverse events and medically attended adverse events will be recorded for the entire study duration (2 years). [2.5.5, 2.5.5.5.1.1] Among the 30,346 participants who had received at least 1 dose of vaccine or placebo (vaccine=15,184, placebo=15,162), unsolicited adverse events that occurred within 28 days following each vaccination were reported by 31.3% of participants (n=4,752) who received SPIKEVAX and 28.6% of participants (n=4,338) who received placebo. [Table 14.3.1.7.1.1]

Lymphadenopathy-related events were reported by 1.7% of vaccine recipients and 0.8% of placebo recipients. These events included lymphadenopathy, lymphadenitis, lymph node pain, vaccination-site lymphadenopathy, injection-site lymphadenopathy, and axillary mass. This imbalance is consistent with the imbalance observed for solicited axillary swelling/tenderness at the injected arm. [2.5.5.5.2.1, Table 14.3.1.11.1.1]

Hypersensitivity adverse events were reported in 2.2% of vaccine recipients and 1.8% of placebo recipients. Hypersensitivity events in the vaccine group included injection site rash and injection site urticaria, which are likely related to vaccination. [Table 14.3.1.22.2, 2.5.5.6.6.1] Delayed injection site reactions that began >7 days after vaccination were reported in 2.4% of vaccine recipients and 1.4% of placebo recipients. Delayed injection site reactions included pain, erythema, and swelling and are likely related to vaccination. [Table 14.3.1.21.1.4]

There were 8 reports of facial paralysis (including Bell's palsy) in the SPIKEVAX group, and 3 in the placebo group. In the 28-day period after vaccination, there were two cases of facial paralysis in the SPIKEVAX group, which occurred on 8 and 22 days, respectively, after vaccination, and one in the placebo group, which occurred 17 days after vaccination. Currently available information on facial paralysis is insufficient to determine a causal relationship with the vaccine. [P301 Part A CSR 7.2.2]

There were no other notable patterns or numerical imbalances between treatment groups for specific categories of adverse events (including other neurologic, neuro-inflammatory, and thrombotic events) that would suggest a causal relationship to SPIKEVAX. [2.5.5.5.2.1]

Serious Adverse Events

Serious adverse events were reported by 1.8% (n=268) of participants who received SPIKEVAX and 1.9% (n=292) of participants who received placebo. [Table 14.3.1.13.1.3]

There were three serious adverse events of facial swelling in vaccine and placebo recipients with a history of injection of dermatological fillers. Two cases occurred in the vaccine group with onset of swelling reported 1 and 3 days, respectively, after vaccination, and one case in the placebo group with onset of swelling reported at 7 days after vaccination. [P301 Part A CSR 7.3.2]

There were no other notable patterns or imbalances between treatment groups for specific categories of serious adverse events (including neurologic, neuro-inflammatory, and thrombotic events) that would suggest a causal relationship to SPIKEVAX. [2.5.5.6.2.1]

6.2 Emergency Use Authorization Experience

The following adverse reactions have been identified during emergency use authorization of SPIKEVAX (Moderna COVID-19 Vaccine). Because these reactions are reported voluntarily, it is not always possible to reliably estimate their frequency or establish a causal relationship to vaccine exposure. [2.5.6.3]

Cardiac Disorders: myocarditis, pericarditis
Immune System Disorders: anaphylaxis

7 DRUG INTERACTIONS

There are no data to assess the concomitant administration of SPIKEVAX with other vaccines.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Exposure Registry

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to SPIKEVAX during pregnancy. Women who are vaccinated with SPIKEVAX during pregnancy are encouraged to enroll in the registry by calling 1-866-MODERNA (1-866-663-3762).

Risk Summary

All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Available data on SPIKEVAX administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy. [2.5.6.3.1]

Data

Animal Data

In a developmental toxicity study, 0.2 mL of a vaccine formulation containing the same quantity of nucleoside-modified messenger ribonucleic acid (mRNA) (100 mcg) and other ingredients included in a single human dose of SPIKEVAX was administered to female rats by the intramuscular route on four occasions: 28 and 14 days prior to mating, and on gestation days 1 and 13. No vaccine-related adverse effects on female fertility, fetal development, or postnatal development were reported in the study. [2.4.4.3, BLA 125752 SN0001 4.2.3.5.2]

8.2 Lactation

Risk Summary

Data are not sufficient to assess the effects of SPIKEVAX on the breastfed infant or on milk production/excretion. [2.5.6.3.1]

Data

Animal Data

In a developmental toxicity study of female rats that received a single human dose of SPIKEVAX (100 mcg), transfer of IgG antibodies was observed in pups at lactation day 21. [2.4.4.3]

8.4 Pediatric Use

Safety and effectiveness have not been established in persons less than 18 years of age.

8.5 Geriatric Use

Clinical studies of SPIKEVAX included participants 65 years of age and older receiving vaccine or placebo, and their data contribute to the overall assessment of safety and efficacy. In an ongoing Phase 3 clinical study, 24.8% (n=7,520) of participants were 65 years of age and older and 4.6% (n=1,399) of participants were 75 years of age and older. [Table 14.1.3.2.2] Vaccine efficacy in participants 65 years of age and older was 91.5% (95% CI 83.2, 95.7) compared to 93.4% (95% CI 91.1, 95.1) in participants 18 to <65 years of age [see *Clinical Studies (14)*]. [Table 14.2.2.1.3.6.1.1] Subjects 65 years of age and older reported solicited local and systemic adverse reactions at a lower rate than subjects 18-64 years of age [see *Adverse Reactions (6.1)*]. [2.5.5.7.1.1, 2.5.5.7.1.2]

11 DESCRIPTION

SPIKEVAX is provided as a white to off-white suspension for intramuscular injection. [BLA 125752 SN002 3.2.P.2.1, 3.2.P.2.2] Each 0.5 mL dose of SPIKEVAX contains 100 mcg of nucleoside-modified messenger RNA (mRNA) encoding the pre-fusion stabilized Spike glycoprotein (S) of SARS-CoV-2 virus. [BLA 125752 SN002 3.2.P.1]

Each dose of the SPIKEVAX contains the following ingredients: a total lipid content of 1.93 mg (SM-102, polyethylene glycol [PEG] 2000 dimyristoyl glycerol [DMG], cholesterol, and 1,2-distearoyl-sn-glycero-3-phosphocholine [DSPC]), 0.31 mg tromethamine, 1.18 mg tromethamine hydrochloride, 0.043 mg acetic acid, 0.20 mg sodium acetate trihydrate, and 43.5 mg sucrose. [BLA 125752 SN002 3.2.P.1]

SPIKEVAX does not contain a preservative. [BLA 125752 SN002 3.2.P.2.1]

The vial stoppers are not made with natural rubber latex. [BLA 125752 SN002 3.2.P.7]

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

The nucleoside-modified mRNA in the SPIKEVAX is formulated in lipid particles, which enable delivery of the nucleoside-modified mRNA into host cells to allow expression of the SARS-CoV-2 S antigen. The vaccine elicits an immune response to the S antigen, which protects against COVID-19. [2.5.1.1.2]

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

SPIKEVAX has not been evaluated for carcinogenic or mutagenic potential, or male infertility in animals. A developmental toxicity study was conducted in rats that received a vaccine formulation containing the same quantity of nucleoside-modified messenger ribonucleic acid (mRNA) (100 mcg) and other ingredients included in a single human dose of SPIKEVAX. No impact on female fertility was reported (*see Pregnancy [8.1]*). [2.4.4.3]

14 CLINICAL STUDIES

Study 1 was a Phase 3 randomized, placebo-controlled, observer-blind clinical trial to evaluate the efficacy, safety, and immunogenicity of SPIKEVAX in participants 18 years of age and older in the United States. Randomization was stratified by age and health risk: 18 to <65 years of age without comorbidities (not at risk for progression to severe COVID-19), 18 to <65 years of age with comorbidities (at risk for progression to severe COVID-19), and 65 years of age and older with or without comorbidities. Participants who were immunocompromised and those with a known history of SARS-CoV-2 infection were excluded from the study. The study allowed for the inclusion of participants with stable pre-existing medical conditions, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 3 months before enrollment, as well as participants with stable human immunodeficiency virus (HIV) infection. [2.5.1.4.2, 2.5.4.1.1] A total of 30,415 participants were randomized equally to receive 2 doses of SPIKEVAX or saline placebo 1 month apart. [Table 14.1.1.1.2] Participants will be followed for efficacy and safety until 2 years after the second dose. [2.5.1.4.2]

The primary efficacy analysis population (referred to as the Per-Protocol Set) included 28,451 participants who received two doses (at 0 and 1 month) of either SPIKEVAX (n=14,287) or placebo (n=14,164), and had a negative baseline SARS-CoV-2 status. [Table 14.2.2.1.3.1.1] In the Per-Protocol Set, 47.5% of participants were female, 19.7% were Hispanic or Latino; 79.7% were White, 9.7% were African American, 4.7% were Asian, and 2.0% other races. The median age of participants was 53 years (range 18-95) and 25.4% of participants were 65 years of age and older. Of the study participants in the Per-Protocol Set, 18.5% were at increased risk of severe COVID-19 due to at least one pre-existing medical condition (chronic lung disease,

significant cardiac disease, severe obesity, diabetes, liver disease, or HIV infection) regardless of age. [Table 14.1.3.4.2] There were no notable differences in demographics or pre-existing medical conditions between participants who received SPIKEVAX and those who received placebo. [2.5.4.1.1]

The median length of follow up for participants in the study was 6 months following Dose 2. [Table 14.1.6.2.1]

Efficacy Against COVID-19

COVID-19 was defined based on the following criteria: The participant must have experienced at least two of the following systemic symptoms: fever ($\geq 38^{\circ}\text{C}$ / $\geq 100.4^{\circ}\text{F}$), chills, myalgia, headache, sore throat, new olfactory and taste disorder(s); or the participant must have experienced at least one of the following respiratory signs/symptoms: cough, shortness of breath or difficulty breathing, or clinical or radiographical evidence of pneumonia; and the participant must have at least one NP swab, nasal swab, or saliva sample (or respiratory sample, if hospitalized) positive for SARS- CoV-2 by RT-PCR. COVID-19 cases were adjudicated by a Clinical Adjudication Committee. [2.5.4.3.1.1]

SPIKEVAX significantly reduced the risk of COVID-19 infection compared to placebo. There were 55 COVID-19 cases in the SPIKEVAX group and 744 cases in the placebo group, with a vaccine efficacy of 93.2% (95% confidence interval of 91.0% to 94.8%) (Table 3). Protection was demonstrated starting 14 days after Dose 2 with duration of protection through 6 months. [Table 14.2.2.1.3.1.1, 2.5.4.4.1.1, 2.5.6.2.1]

Table 3: Primary Efficacy Analysis: COVID-19* in Participants 18 Years of Age and Older Starting 14 Days After Dose 2 per Adjudication Committee Assessments – Per-Protocol Set
[Table 14.2.2.1.3.1.1]

SPIKEVAX			Placebo			% Vaccine Efficacy (95% CI)†
Participants (N)	COVID-19 Cases (n)	Incidence Rate of COVID-19 per 1,000 Person-Years	Participants (N)	COVID-19 Cases (n)	Incidence Rate of COVID-19 per 1,000 Person-Years	
14,287	55	9.599	14,164	744	136.633	93.2 (91.0, 94.8)

* COVID-19: symptomatic COVID-19 requiring positive RT-PCR result and at least two systemic symptoms or one respiratory symptom. Cases starting 14 days after Dose 2.

† VE and 95% CI from the stratified Cox proportional hazard model.

The subgroup analyses of vaccine efficacy are presented in Table 4.

Table 4: Subgroup Analyses of Vaccine Efficacy: COVID-19* Cases Starting 14 Days After Dose 2 per Adjudication Committee Assessments – Per-Protocol Set [Table 14.2.2.1.3.6.1.1, Table 14.2.2.1.3.6.2.1]

Age Subgroup (Years)	SPIKEVAX			Placebo			% Vaccine Efficacy (95% CI)†
	Participants (N)	COVID-19 Cases (n)	Incidence Rate of COVID-19 per 1,000 Person-Years	Participants (N)	COVID-19 Cases (n)	Incidence Rate of COVID-19 per 1,000 Person-Years	
18 to <65	10,661	46	10.742	10,569	644	158.958	93.4 (91.1, 95.1)
≥65	3,626	9	6.217	3,595	100	71.744	91.5 (83.2, 95.7)
65 to <75	2,990	9	7.546	2,898	81	71.980	89.7 (79.6, 94.9)
≥75	636	0	0.000	697	19	70.755	100.0 (NE, 100.0)

NE = Not estimable

* COVID-19: symptomatic COVID-19 requiring positive RT-PCR result and at least two systemic symptoms or one respiratory symptom. Cases starting 14 days after Dose 2.

† VE and 95% CI from the stratified Cox proportional hazard model.

Severe COVID-19 was defined based on confirmed COVID-19 as per the primary efficacy endpoint case definition, plus any of the following: Clinical signs indicative of severe systemic illness, respiratory rate ≥ 30 per minute, heart rate ≥ 125 beats per minute, SpO₂ $\leq 93\%$ on room air at sea level or PaO₂/FIO₂ < 300 mm Hg; or respiratory failure or ARDS (defined as needing high-flow oxygen, non-invasive or mechanical ventilation, or ECMO), evidence of shock (systolic blood pressure < 90 mmHg, diastolic BP < 60 mmHg or requiring vasopressors); or significant acute renal, hepatic, or neurologic dysfunction; or admission to an intensive care unit or death. [2.5.4.3.1.1]

Among all participants in the Per-Protocol Set analysis, which included COVID-19 cases confirmed by an adjudication committee, 2 cases of severe COVID-19 were reported in the SPIKEVAX group compared with 106 cases reported in the placebo group, with a vaccine efficacy of 98.2% (95% confidence interval of 92.8% to 99.6%) (Table 5). [Table 14.2.2.2.3.1.1]

Table 5: Efficacy Analysis: Severe COVID-19* in Participants 18 Years of Age and Older Starting 14 Days After Dose 2 per Adjudication Committee Assessments – Per-Protocol Set [Table 14.2.2.2.3.1.1]

SPIKEVAX			Placebo			% Vaccine Efficacy (95% CI)†
Participants (N)	COVID-19 Cases (n)	Incidence Rate of COVID-19 per 1,000 Person-Years	Participants (N)	COVID-19 Cases (n)	Incidence Rate of COVID-19 per 1,000 Person-Years	
14,287	2	0.349	14,164	106	19.112	98.2 (92.8, 99.6)

* Severe COVID-19: symptomatic COVID-19 requiring positive RT-PCR result and at least two systemic symptoms or one respiratory symptom, plus any of the following: Clinical signs indicative of severe systemic illness, respiratory rate ≥ 30 per minute, heart rate ≥ 125 beats per minute, SpO₂ $\leq 93\%$ on room air at sea level or PaO₂/FIO₂ < 300 mm Hg; or respiratory failure or ARDS (defined as needing high-flow oxygen, non-invasive or mechanical ventilation, or ECMO), evidence of shock (systolic blood pressure < 90 mmHg, diastolic BP < 60 mmHg or requiring vasopressors); or significant acute renal, hepatic, or neurologic dysfunction; or admission to an intensive care unit or death. Cases starting 14 days after Dose 2.

† VE and 95% CI from the stratified Cox proportional hazard model.

Prevention of asymptomatic SARS-CoV-2 infection was analyzed using the Per-Protocol Set and identified by seroconversion against nucleocapsid protein (by the Elecsys immunoassay) and/or detection by RT-PCR in the absence of symptoms. [2.7.3.1.1.1, 2.7.3.2.1.1]

Among all participants in the Per-Protocol Set analysis, 214 cases of asymptomatic SARS-CoV-2 infection were reported in the SPIKEVAX group compared with 498 cases reported in the placebo group, with a vaccine efficacy of 63.0% (95% confidence interval of 56.6% to 68.5%) (Table 6). [2.7.3.2.1.1]

Table 6: Efficacy Analysis: Asymptomatic SARS-CoV-2 Infection* in Participants 18 Years of Age and Older Starting 14 Days After Dose 2 – Per-Protocol Set [2.7.3.2.1.1, 2.7.3.1.1.1]

SPIKEVAX		Placebo		% Vaccine Efficacy (95% CI)†
Participants (N)	Asymptomatic SARS-CoV-2 Infection Cases (n)	Participants (N)	Asymptomatic SARS-CoV-2 Infection Cases (n)	
14,287	214	14,164	498	63.0 (56.6, 68.5)

* Asymptomatic SARS-CoV-2 infection: Absence of COVID-19 symptoms from either the primary efficacy endpoint case definition or secondary definition of COVID-19. Primary endpoint case definition = at least two of the following symptom: fever ($\geq 38^\circ\text{C}$ / $\geq 100.4^\circ\text{F}$), chills, myalgia, headache, sore throat, new olfactory and taste disorder(s); or the participant must have experienced at least one of the following respiratory signs/symptoms: cough, shortness of breath or difficulty breathing, or clinical or radiographical evidence of pneumonia; and the participant must have at least one NP swab, nasal swab, or saliva sample (or respiratory sample, if hospitalized)

positive for SARS-CoV-2 by RT-PCR). Secondary definition = presence of at least one symptom from a list of COVID-19 symptoms and a positive NP swab or saliva sample for SARS-CoV-2 by RT-PCR. Listed symptoms were fever (temperature $>38^{\circ}\text{C}$ / $\geq 100.4^{\circ}\text{F}$), or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle aches, or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea, or vomiting or diarrhea) and at least one of either seroconversion at scheduled visits when blood samples for immunogenicity were collected or by RT-PCR at scheduled visits. Cases starting 14 days after Dose 2.

† VE and 95% CI from the Fine and Gray's sub-distribution hazard model.

16 HOW SUPPLIED/STORAGE AND HANDLING

SPIKEVAX Suspension for Intramuscular Injection Multiple-Dose Vials are supplied as follows: [BLA 125752 SN002 3.2.P.1, 3.2.P.3.3]

NDC 80777-100-99 Carton of 10 multiple-dose vials, each vial containing 5.5 mL

NDC 80777-100-98 Carton of 10 multiple-dose vials, each vial containing 7.5 mL

During storage, minimize exposure to room light. [BLA 125752 SN002 3.2.P.2.2]

Store frozen between -50° to -15°C (-58° to 5°F). [BLA 125752 SN002 3.2.P.8.1, 3.2.P.8.3]

Store in the original carton to protect from light. [BLA 125752 SN002 3.2.P.2.2]

Vials may be stored refrigerated between 2° to 8°C (36° to 46°F) for up to 30 days prior to first use. Do not refreeze. [BLA 125752 SN002 3.2.P.2.6, 3.2.P.8.1, 3.2.P.8.3]

Vials may be stored between 8° to 25°C (46° to 77°F) for a total of 24 hours. [BLA 125752 SN002 3.2.P.2.6, 3.2.P.8.1, 3.2.P.8.3]

After the first dose has been withdrawn, the vial should be held between 2° to 25°C (36° to 77°F). Vials should be discarded 12 hours after the first puncture. [BLA 125752 SN002 3.2.P.2.6, 3.2.P.8.1, 3.2.P.8.3]

Thawed vials can be handled in room light conditions. [BLA 125752 SN002 3.2.P.2.2]

Do not refreeze once thawed. [BLA 125752 SN002 3.2.P.2.2, 3.2.P.2.6]

Transportation of Thawed Vials at 2° to 8°C (36° to 46°F)

If transport at -50° to -15°C (-58° to 5°F) is not feasible, available data support transportation of one or more thawed vials for up to 12 hours at 2° to 8°C (36° to 46°F) when shipped using shipping containers which have been qualified to maintain 2° to 8°C (36° to 46°F) and under routine road and air transport conditions with shaking and vibration minimized. Once thawed and transported at 2° to 8°C (36° to 46°F), vials should not be refrozen and should be stored at 2° to 8°C (36° to 46°F) until use. [BLA 125752 SN002 3.2.P.2.2]

17 PATIENT COUNSELING INFORMATION

Advise the vaccine recipient or caregiver to read the FDA-approved patient labeling (Information

for Recipients and Caregivers).

Inform the vaccine recipient or caregiver of the potential benefits and risks of immunization with SPIKEVAX.

Inform the vaccine recipient or caregiver that SPIKEVAX does not contain SARS-CoV-2 and cannot give them COVID-19. SPIKEVAX stimulates the immune system to produce antibodies that protect against COVID-19.

Inform the vaccine recipient or caregiver of the need for two doses administered 1 month apart. The full effect of the vaccine is generally achieved approximately 2 weeks after vaccination.

Instruct the vaccine recipient or caregiver to report any severe or unusual adverse reactions to their healthcare provider.

Encourage women who receive SPIKEVAX while pregnant to enroll in the pregnancy exposure registry. Pregnant women can enroll in the pregnancy exposure registry by calling 1-866-MODERNA (1-866-663-3762).

Provide the vaccine recipient Vaccine Information Statements prior to immunization. These materials are available free of charge at the Centers for Disease Control and Prevention (CDC) website (www.cdc.gov/vaccines).

Manufactured for:
Moderna US, Inc.
Cambridge, MA 02139

©2021 ModernaTX, Inc. All rights reserved.
SPIKEVAX is a trademark of ModernaTX, Inc.
Patent(s): www.modernatx.com/patents
Revised: 00/2021